Duloxetine replaces escitalopram once painful diabetic neuropathy joins a composite supervisor's depression, and the MN663 Unit 7 case study adds hepatic, renal and blood pressure checks to match. Searches like "mn 663 unit 7 assignment example", "mn663 unit 7 sample" and "mn663 unit 7 example" land here.
One Medication for Two Diagnoses? Revising a Depression Plan When Painful Diabetic Neuropathy Appears
[Student Name]
Purdue University Global
MN663: PMHNP Diagnosis and Management Across the Lifespan I
Unit 7 Assignment
[Instructor Name]
[Date]
Composite patient written as a model document. Doses and switch schedules are bracketed; nothing here is a prescribing instruction.
Case Summary
A composite 52-year-old road crew supervisor with type 2 diabetes began escitalopram six weeks ago for major depressive disorder. His PHQ-9 has fallen from 18 to 13, a partial response. At this visit he describes burning and pins and needles in both feet that are worst at bedtime and keep him awake, and his primary care provider has diagnosed diabetic peripheral neuropathy. New facts: hemoglobin A1c 8.2 percent; estimated glomerular filtration rate 74 mL/min/1.73 m2; blood pressure 134/84; liver enzymes normal; alcohol about two drinks a week. He operates heavy equipment at work. He takes metformin and lisinopril. He has had diabetes for nine years and admits that his glucose control slipped during the months his mood was worst, when he stopped checking his sugars and ate irregularly on the road. His wife has noticed that he is less irritable than before starting escitalopram but still withdrawn in the evenings. He has no history of mania, no suicidal thoughts and no prior antidepressant trials.
Original Plan, Reproduced
Diagnosis: major depressive disorder, moderate. Medication: escitalopram at a [composite dose]. Psychotherapy: referral for cognitive behavioral therapy, attended twice. Monitoring: PHQ-9 at each visit, suicidal thoughts asked at each visit. Follow-up: every four weeks.
Options Weighed
Option 1: keep escitalopram and add pregabalin. Pregabalin is recommended as an initial treatment for painful diabetic neuropathy (Pop-Busui et al., 2017). But it adds a second medication with its own sedation and dizziness, which matters for a man who operates heavy equipment, and it does nothing further for his depression, which has only partly responded.
Option 2: switch escitalopram to duloxetine. Duloxetine is also recommended as an initial treatment for neuropathic pain in diabetes (Pop-Busui et al., 2017), and it carries FDA indications for both major depressive disorder and diabetic peripheral neuropathic pain (Eli Lilly and Company, 2023). A switch gives him one drug instead of two and changes the mechanism after a partial response to an SSRI.
Option 3: add amitriptyline. Tricyclic antidepressants have evidence in neuropathic pain, and the paper credits it. But amitriptyline carries anticholinergic effects, sedation and concerns about cardiac conduction and overdose toxicity, and combining it with an SSRI adds serotonergic load. For a man with depression and a job requiring alertness, those risks outweigh its benefit.
Choice
Duloxetine is chosen because it treats both conditions with a single agent, avoids adding a second sedating drug for a man who operates heavy equipment, and offers a change of mechanism after a partial response. The switch is made as [a cross-taper over a composite interval], with the specifics recorded in the medication plan rather than in this paper.
Evidence for Duloxetine in Neuropathic Pain
A Cochrane review of duloxetine for painful neuropathy found moderate-quality evidence that it reduces pain in diabetic peripheral neuropathy, with a number needed to treat of about five for a 50 percent reduction in pain at the commonly studied dose (Lunn et al., 2014). Adverse effects, mainly nausea, sleepiness and dizziness, led some patients to stop. That evidence supports its use here, and the side effects named are the ones he will be asked about, particularly sleepiness given his work.
Talking With Him About the Change
He was asked what mattered most to him. He said sleep, because the foot pain wakes him at 2 a.m. and he has to be at the job site by 6:30, and not taking "a pile of pills." Both priorities favor a single medication. He was told honestly that duloxetine may take several weeks to help his mood fully, that pain relief often begins sooner, and that nausea is common in the first week and usually fades. He agreed to the switch and to calling if he felt drowsy at work or noticed agitation or sweating during the changeover.
What the Change Newly Requires
Glucose. Duloxetine has been associated with small increases in fasting glucose in some patients with diabetes, so his endocrinologist is informed of the change and his glucose logs are reviewed at each visit, with an A1c at three months.
Liver. Duloxetine carries a caution about liver injury and should generally be avoided in people with substantial alcohol use or chronic liver disease; his liver enzymes are normal and his alcohol intake is low, so it can be used, with enzymes checked if symptoms suggest liver injury and repeated at three months.
Kidneys. Duloxetine is not recommended in severe kidney impairment. His eGFR of 74 is well above that range, and it will be rechecked with his routine diabetes labs.
Blood pressure. Duloxetine can raise blood pressure slightly, so his pressure is checked at each visit, with review if it rises above 140/90.
Discontinuation. Stopping duloxetine abruptly can cause dizziness, nausea and irritability, so he is told not to stop it on his own.
Coordination
The revised plan is sent to his primary care provider and endocrinologist with a short summary: the reason for the switch, the glucose and blood pressure checks, and a request to notify the psychiatric nurse practitioner of any new medication. Because escitalopram and duloxetine both affect serotonin, the cross-taper is supervised with a check-in call during the switch to ask about agitation, sweating, tremor or diarrhea.
Revised Monitoring
PHQ-9 at each visit; neuropathic pain rated 0 to 10 each visit; suicidal thoughts asked at each visit; blood pressure each visit; glucose logs reviewed each visit; A1c and liver enzymes at three months; sleep and daytime alertness asked each visit, with a specific question about alertness at work.
If the Switch Does Not Work
If his pain has not improved after an adequate trial at a full dose, pregabalin can be added, accepting its sedation with careful attention to his work. If his depression has not improved, the plan returns to the options for partial response, including more intensive psychotherapy, which he has attended only twice.
Conclusion
A single medication can reasonably serve both diagnoses in this case, but the choice brings new monitoring and new coordination. The revision is judged at eight weeks against two measures: a PHQ-9 below 10 and a meaningful drop in his foot pain, which he will rate each night in a simple diary so that the change is measured over time rather than remembered.
References
Eli Lilly and Company. (2023). Cymbalta (duloxetine delayed-release capsules): Prescribing information. Eli Lilly and Company.
Lunn, M. P. T., Hughes, R. A. C., & Wiffen, P. J. (2014). Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews, 2014(1), CD007115. https://doi.org/10.1002/14651858.CD007115.pub3
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017). Diabetic neuropathy: A position statement by the American Diabetes Association. Diabetes Care, 40(1), 136-154. https://doi.org/10.2337/dc16-2042
How this MN663 Unit 7 example is structured
What changed organizes the paper, not the two diagnoses taken separately. After the summary, a before-and-after layout sets the original plan beside the revised one, row by row, so every alteration is visible and carries its reason. The options section treats amitriptyline fairly, crediting its evidence in neuropathic pain, then rejects it for anticholinergic burden and cardiac conduction concerns. Pregabalin is rejected more narrowly: a second agent adds sedation and dizziness for a man who operates heavy equipment. The switch is described as [a cross-taper over a composite interval], its specifics bracketed. Coordination gets its own paragraph, with the endocrinologist informed and glucose watched because duloxetine has been associated with small rises in fasting glucose. Liver, kidney and pressure thresholds complete the revision, each tied to a label caution.
Get an MN663 Unit 7 example written to your instructions
Is the second condition named in your MN663 Unit 7 prompt, or is the writer asked to introduce one? Include the case, any earlier plan and the rubric. Original and revised plans side by side, each change reasoned and monitoring rebuilt for the new combination: that is what the free first case study delivers within 24-48h. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
MN663 Unit 7 questions, answered
Should the paper keep the first medication if it partly worked?
Sometimes, and the paper should consider it openly. A partial response can argue for continuing and adding, or for switching to something that covers both conditions. What matters is that the choice is argued from the case: the size of the response, the new condition's demands and the burden of two drugs against one.
How much should the paper say about the medical condition itself?
Enough to show how it changes psychiatric management, and little more. For diabetic neuropathy that means its symptoms, its effect on sleep and mood, and the treatments that overlap with depression care. A full account of glycemic management belongs to another clinician, and the paper should name that clinician rather than attempt their plan.
Is it appropriate to recommend involving another specialist?
Yes, and graders usually expect it when a second condition belongs to another service. State who is contacted, what they are told and what the psychiatric plan needs from them, such as glucose results. A plan that treats a medical condition in isolation from the clinicians managing it reads as incomplete, however sound its pharmacology.